The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.
 
Jeremie Calais
Stock and Other Ownership Interests - Endocyte
 
Wolfgang P Fendler
Consulting or Advisory Role - Endocyte; Ipsen; Radiomedix
 
Matthias Eiber
Research Funding - Siemens
Travel, Accommodations, Expenses - Bayer Schering Pharma
 
MIchael Lassmann
No Relationships to Disclose
 
Magnus Dahlbom
No Relationships to Disclose
 
Rouzbeh Esfandiari
No Relationships to Disclose
 
Jeannine Gartmann
No Relationships to Disclose
 
Kathleen Nguyen
No Relationships to Disclose
 
Pan Thin
No Relationships to Disclose
 
Vincent Lok
No Relationships to Disclose
 
Ken Herrmann
No Relationships to Disclose
 
Johannes Czernin
Leadership - SOFIE
Stock and Other Ownership Interests - SOFIE
Consulting or Advisory Role - Actinium Pharmaceuticals; Endocyte; SOFIE; Trethera
 
Ebrahim Delpassand
Employment - Radiomedix
Stock and Other Ownership Interests - Endocyte; Radiomedix
Honoraria - Advanced Accelerator Applications/Novartis; Endocyte
Consulting or Advisory Role - Endocyte
Speakers' Bureau - Advanced Accelerator Applications/Novartis; Bayer
Patents, Royalties, Other Intellectual Property - Curium Pharma. Licensing Agreement. (Inst)
Travel, Accommodations, Expenses - Endocyte